Anti Cancer Drugs

Top headlines: Rupee at 5-week high; Infosys says no to moonlighting

As many as 34 new drugs were added and 26 dropped from an updated list of essential medicines that will lead to prices being fixed, said the government on Tuesday.

NLEM: Several anti-cancer drugs, antibiotics to become more affordable

Thirty-four drugs, including some anti-infectives such as Ivermectin, Mupirocin and Nicotine Replacement Therapy, have been added to the National List of Essential Medicines taking the total drugs under it to 384. Several antibiotics, vaccines and anti-cancer drugs will become more affordable by their addition to the list. However, 26 drugs such as Ranitidine, Sucralfate, white petrolatum, Atenolol and Methyldopa have been deleted from the revised list. The deletion has been done based on the parameters of cost effectiveness and availability of better drugs. Union Health Minister Mansukh Mandaviya, who released the list on Tuesday, tweeted, "Released the National List of Essential Medicines 2022.It comprises 384 drugs across 27 categories.Several antibiotics, vaccines, anti-cancer drugs and many other important drugs will become more affordable & reduce patients' out-of-pocket expenditure." Endocrine medicines and contraceptives Fludrocortisone, Ormeloxifene, Insulin Glargine and

NIM inclusion of anti-cancer vaccine may start with 9-14 year olds

The inclusion of this vaccine in the NIM is a significant step in reducing cervical cancer burden among women

Scientists find new class of drugs that may treat blood, bone marrow cancer

A group of scientists in the US, including an Indian-American from the prestigious Cleveland Clinic, have identified a potential new class of drugs that may prove effective in treating certain common types of blood and bone marrow cancers. First published in the latest edition of Blood Cancer Discovery, the decade long research which reports that a new pharmacological strategy to preferentially target and eliminate leukemia cells with TET2 mutations, was carried out by Jaroslaw Maciejewski and his collaborator Babal Kant Jha from the Cleveland Clinic Department of Translational Hematology & Oncology Research. Myeloid leukemias are cancers derived from stem and progenitor cells in the bone marrow that give rise to all normal blood cells. One of the most common mutations involved in driving myeloid leukemias are found in the TET2 gene, which has been investigated for the last decade by Maciejewski and Jha. In preclinical models, we found that a synthetic molecule called TETi76 was ..

AstraZeneca agrees to pay Japan's Daiichi $6 bn for new cancer drug

The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said

Cancer-fighting potential in nearly 50 drugs for other conditions: Study

"We found that a surprising number of non-oncology drugs are able to kill cancer cell lines in the lab," said Steven Corsello of Dana-Farber Cancer Institute

Cancer drugs may be effective in treating chronic lung inflammation: Study

Researchers, including those from the University of Sheffield in the UK, assessed the effect of drugs used to treat different cancer types on lung damage in people living with COPD

Lupin, Boehringer Ingelheim ink $700-mn deal for anti-cancer drug

Lupin will get the marketing rights for the drug in India, while Boehringer Ingelheim will hold the rights to all other markets

42 more cancer drugs under price control, profit margin cap at 30%

The NPPA has the right to cap prices of scheduled drugs, or use extraordinary powers in case of other drugs